Browse
We’re here to help

Find guidance on Author Services

Login | Register

Login
Register

Cart Add to Cart

Search
Browse
We’re here to help

Find guidance on Author Services

Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 30, Issue 8

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

About this journalAbout

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Investigational Drugs, Volume 30, Issue 8 (2021)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 30, Issue 8 (2021)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Volume 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Low-dose aspirin for early COVID-19: does the early bird catch the worm?

John G. Rizk, Carl J. Lavie & Ajay Gupta

Pages: 785-788

Published online: 12 Jul 2021

First Page PreviewforLow-dose aspirin for early COVID-19: does the early bird catch the worm? | Full Text | References | PDF (951 KB) | EPUB

53207 Views
9 CrossRef citations
0Altmetric

Free Access

Editorial

Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

Alicia F. C. Okines & Lara Ulrich

Pages: 789-795

Published online: 21 Jun 2021

First Page PreviewforInvestigational antibody-drug conjugates in clinical trials for the treatment of breast cancer | Full Text | References | PDF (612.4 KB) | EPUB

1985 Views
2 CrossRef citations
0Altmetric

Free Access

Key Paper Evaluation

Article

Still grasping at straws: donanemab in Alzheimer’s disease

Sheila A Doggrell

Pages: 797-801

Published online: 08 Jul 2021

AbstractforStill grasping at straws: donanemab in Alzheimer’s disease | Full Text | References | PDF (212.8 KB) | EPUB

851 Views
4 CrossRef citations
0Altmetric

Drug Evaluation

Article

Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

Massimo Breccia, Gioia Colafigli, Emilia Scalzulli & Maurizio Martelli

Pages: 803-811

Published online: 24 Jun 2021

AbstractforAsciminib: an investigational agent for the treatment of chronic myeloid leukemia | Full Text | References | PDF (331.2 KB) | EPUB

876 Views
12 CrossRef citations
0Altmetric

Review

Anti-diabetic drugs and NASH: from current options to promising perspectives

Sarra Smati, Clémence M Canivet, Jérôme Boursier & Bertrand Cariou

Pages: 813-825

Published online: 12 Jul 2021

AbstractforAnti-diabetic drugs and NASH: from current options to promising perspectives | Full Text | References | PDF (411.1 KB) | EPUB

887 Views
11 CrossRef citations
0Altmetric

Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver

D. Brock Hewitt, Amir A. Rahnemai-Azar & Timothy M. Pawlik

Pages: 827-835

Published online: 15 Jun 2021

AbstractforPotential experimental immune checkpoint inhibitors for the treatment of cancer of the liver | Full Text | References | PDF (368.6 KB) | EPUB

324 Views
1 CrossRef citations
0Altmetric

Bladder cancer: shedding light on the most promising investigational drugs in clinical trials

Irbaz Bin Riaz, Ahsan Masood Khan, James WF Catto & Syed A Hussain

Pages: 837-855

Published online: 14 Jul 2021

AbstractforBladder cancer: shedding light on the most promising investigational drugs in clinical trials | Full Text | References | PDF (6.8 MB) | EPUB

4317 Views
10 CrossRef citations
0Altmetric

Open Access

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Rujapope Sutiwisesak, Terry C. Burns, Moses Rodriguez & Arthur E. Warrington

Pages: 857-876

Published online: 24 Jun 2021

AbstractforRemyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials | Full Text | References | PDF (1.3 MB) | EPUB

790 Views
4 CrossRef citations
0Altmetric

Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential

Jonathan Flintoff, James P Kesby, Dan Siskind & Thomas HJ Burne

Pages: 877-891

Published online: 09 Jul 2021

AbstractforTreating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential | Full Text | References | PDF (407 KB) | EPUB

578 Views
7 CrossRef citations
0Altmetric

Original Research

Article

Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers

Michael Derks, Sian Lennon-Chrimes, Andreas Guenther, Lisa Squassante, Christoph Wandel, Piotr Szczesny, Axel Paehler & Heidemarie Kletzl

Pages: 893-901

Published online: 16 Jul 2021

228 Views
3 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Early psoriatic arthritis: clinical and therapeutic challenges.

Francesco Caso et al.

Review Article | Published online: 23 Jul 2024

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Elisabeth Amadeo et al.

Review Article | Published online: 22 Jul 2024

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Robert H. Gaffey et al.

Review Article | Published online: 17 Jul 2024

Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects

Jian Liu et al.

Article | Published online: 12 Jul 2024

Open Access

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.30, Iss.8, 2021)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?